Temozolomide Accord 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0063/G 
This was an application for a group of variations. 
26/06/2023 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0062/G 
This was an application for a group of variations. 
31/01/2023 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IA/0061/G 
This was an application for a group of variations. 
24/03/2022 
n/a 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
Page 2/19 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
IB/0060 
C.I.2.a - Change in the SPC, Labelling or PL of a 
18/03/2022 
06/03/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0059 
B.III.1.a.3 - Submission of a new/updated or 
14/12/2021 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
IA/0058/G 
This was an application for a group of variations. 
13/12/2021 
04/02/2022 
Annex II and 
PL 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
Page 3/19 
 
 
 
 
 
 
 
 
 
 
 
 
 
control/testing takes place 
IA/0057/G 
This was an application for a group of variations. 
23/07/2021 
n/a 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IB/0056 
C.I.z - Changes (Safety/Efficacy) of Human and 
07/07/2021 
04/02/2022 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IAIN/0055 
B.II.b.2.c.1 - Change to importer, batch release 
27/01/2021 
04/02/2022 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
Page 4/19 
 
 
 
 
 
 
 
 
 
 
 
 
 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0054/G 
This was an application for a group of variations. 
23/09/2020 
n/a 
B.II.e.1.a.1 - Change in immediate packaging of the 
finished product - Qualitative and quantitative 
composition - Solid pharmaceutical forms 
B.II.e.1.a.1 - Change in immediate packaging of the 
finished product - Qualitative and quantitative 
composition - Solid pharmaceutical forms 
B.II.e.1.z - Change in immediate packaging of the 
finished product - Other variation 
IAIN/0053 
B.II.b.1.a - Replacement or addition of a 
28/08/2020 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0052 
C.I.2.a - Change in the SPC, Labelling or PL of a 
15/06/2020 
19/10/2020 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0051 
B.II.b.1.a - Replacement or addition of a 
17/04/2020 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IA/0050 
B.II.b.2.a - Change to importer, batch release 
26/02/2020 
n/a 
arrangements and quality control testing of the FP - 
Page 5/19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Replacement/addition of a site where batch 
control/testing takes place 
IAIN/0049 
B.II.b.1.a - Replacement or addition of a 
27/01/2020 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0048 
C.I.z - Changes (Safety/Efficacy) of Human and 
20/09/2019 
19/10/2020 
SmPC 
Veterinary Medicinal Products - Other variation 
IA/0047 
B.III.1.a.2 - Submission of a new/updated or 
01/07/2019 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IAIN/0046/G 
This was an application for a group of variations. 
05/03/2019 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
T/0045 
Transfer of Marketing Authorisation 
01/02/2019 
25/02/2019 
SmPC, 
Labelling and 
PL 
IAIN/0044 
B.II.b.2.c.1 - Change to importer, batch release 
27/09/2018 
25/02/2019 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Page 6/19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Not including batch control/testing 
IB/0043 
C.I.2.a - Change in the SPC, Labelling or PL of a 
23/05/2018 
29/06/2018 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IAIN/0042 
B.III.1.a.1 - Submission of a new/updated or 
22/01/2018 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
IB/0041 
C.I.z - Changes (Safety/Efficacy) of Human and 
18/07/2017 
29/06/2018 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IAIN/0040 
B.III.2.a.1 - Change of specification(s) of a former 
18/01/2017 
n/a 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - AS 
IAIN/0039 
B.II.b.1.a - Replacement or addition of a 
19/12/2016 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IA/0038 
A.5.b - Administrative change - Change in the name 
29/09/2016 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
Page 7/19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0037/G 
This was an application for a group of variations. 
27/06/2016 
22/05/2017 
SmPC and PL 
B.II.a.3.b.1 - Changes in the composition 
(excipients) of the finished product - Other excipients 
- Any minor adjustment of the quantitative 
composition of the finished product with respect to 
excipients 
B.II.a.3.z - Changes in the composition (excipients) 
of the finished product - Other variation 
IA/0036 
B.II.b.4.b - Change in the batch size (including batch 
17/02/2016 
n/a 
size ranges) of the finished product - Downscaling 
down to 10-fold 
II/0035 
B.II.d.1.e - Change in the specification parameters 
22/10/2015 
n/a 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
IB/0033 
C.I.2.a - Change in the SPC, Labelling or PL of a 
14/07/2015 
02/06/2016 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0034 
B.II.b.2.c.1 - Change to importer, batch release 
26/06/2015 
02/06/2016 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Page 8/19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0031/G 
This was an application for a group of variations. 
12/06/2015 
02/06/2016 
SmPC, 
Labelling and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.e.1.b.1 - Change in immediate packaging of the 
finished product - Change in type/addition of a new 
container - Solid, semi-solid and non-sterile liquid 
pharmaceutical forms 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
Page 9/19 
 
 
 
 
 
 
 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
Page 10/19 
 
 
 
 
 
the range of the currently approved pack sizes 
IAIN/0032/G 
This was an application for a group of variations. 
05/06/2015 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.c.1.c - Change in the specification parameters 
and/or limits of an excipient - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.II.e.4.a - Change in shape or dimensions of the 
container or closure (immediate packaging) - Non-
sterile medicinal products 
B.II.e.4.a - Change in shape or dimensions of the 
container or closure (immediate packaging) - Non-
sterile medicinal products 
B.II.e.7.b - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
B.III.2.b - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
T/0029 
Transfer of Marketing Authorisation 
10/04/2015 
27/05/2015 
SmPC, 
Labelling and 
Page 11/19 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0030/G 
This was an application for a group of variations. 
18/03/2015 
27/05/2015 
SmPC, 
PL 
A.2.a - Administrative change - Change in the 
(invented) name of the medicinal product for CAPs 
C.I.8.a - Introduction of or changes to a summary of 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
Labelling and 
PL 
R/0026 
Renewal of the marketing authorisation. 
23/10/2014 
12/01/2015 
SmPC, Annex 
Based on the review of the available information, the CHMP 
II, Labelling 
is of the opinion that the quality, the safety and the efficacy 
and PL 
of this medicinal product continues to be adequately and 
sufficiently demonstrated and therefore considers the 
benefit/risk profile of Temozolomide Hospira continues to 
be favourable. 
The CHMP is also of the opinion that the renewal can be 
granted with unlimited validity. 
IG/0477 
C.I.8.a - Introduction of or changes to a summary of 
03/09/2014 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IB/0027 
Update of section 4.8 of the SmPC to include the 
14/08/2014 
12/01/2015 
SmPC and PL 
calculated frequency of hepatic-related disorders 
following adoption of the same changes for the 
reference product. Section 4 of the Package Leaflet 
was updated accordingly. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
Page 12/19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0025 
C.I.2.a - Change in the SPC, Labelling or PL of a 
12/02/2014 
28/02/2014 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0024/G 
This was an application for a group of variations. 
17/12/2013 
n/a 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
Page 13/19 
 
 
 
 
 
 
 
 
 
 
 
IA/0022/G 
This was an application for a group of variations. 
11/12/2013 
n/a 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IG/0382 
C.I.8.a - Introduction of or changes to a summary of 
02/12/2013 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IA/0021 
B.II.e.7.b - Change in supplier of packaging 
14/08/2013 
n/a 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
IG/0317 
C.I.z - Changes (Safety/Efficacy) of Human and 
23/07/2013 
n/a 
Veterinary Medicinal Products - Other variation 
IAIN/0019 
B.II.b.1.a - Replacement or addition of a 
03/06/2013 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IG/0286 
C.I.z - Changes (Safety/Efficacy) of Human and 
12/04/2013 
n/a 
Veterinary Medicinal Products - Other variation 
IB/0016 
C.I.2.a - Change in the SPC, Labelling or PL of a 
04/04/2013 
28/02/2014 
SmPC and PL 
generic/hybrid/biosimilar products following 
Page 14/19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
IA/0017 
B.II.d.2.a - Change in test procedure for the finished 
20/03/2013 
n/a 
product - Minor changes to an approved test 
procedure 
IA/0015 
B.II.d.2.a - Change in test procedure for the finished 
20/12/2012 
n/a 
product - Minor changes to an approved test 
procedure 
IB/0014 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
21/11/2012 
28/02/2014 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0013 
In line with the CHMP adoption of variations to the 
09/10/2012 
25/10/2012 
SmPC, Annex 
II, Labelling 
and PL 
Marketing Authorisation of the Originator Product 
Temodal (EMEA/H/C222/II/59) on 24.05.2012 the 
Product Information (PI) for Temozolomide Hospira 
was updated with changes to the SmPC in order to 
add a warning regarding the risk of 
myelosuppression including prolonged pancytopenia 
following the assessment of PSUR. The package 
leaflet was improved and brought in line accordingly. 
In addition, the Spanish PI translation was brought in 
line with the approved Spanish text of the originator 
product. 
Furthermore, the PI is brought in line with the latest 
Page 15/19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
QRD template, version 8. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
N/0012 
To combine the package leaflets as did the reference 
13/08/2012 
25/10/2012 
PL 
product and to add the list of the local 
representatives in annex IIIB. 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
IB/0010 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
22/06/2012 
25/10/2012 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IAIN/0011 
B.II.b.1.a - Replacement or addition of a 
12/06/2012 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0009/G 
This was an application for a group of variations. 
20/04/2012 
n/a 
C.I.9.a - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change in the 
QPPV 
C.I.9.c - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change of the 
back-up procedure of the QPPV 
Page 16/19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C.I.9.g - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change of the site 
undertaking pharmacovigilance activities 
C.I.9.h - Changes to an existing pharmacovigilance 
system as described in the DDPS - Other change(s) 
to the DDPS that does not impact on the operation of 
the pharmacovigilance system 
IB/0008 
B.II.d.1.z - Change in the specification parameters 
10/01/2012 
n/a 
and/or limits of the finished product - Other variation 
IB/0006 
B.II.f.1.z - Stability of FP - Change in the shelf-life or 
22/11/2011 
25/05/2012 
SmPC 
storage conditions of the finished product - Other 
variation 
IB/0007 
to update section 4.8 of the SmPC for Temozolomide 
21/10/2011 
n/a 
SmPC, 
to update section 4.8 of the SmPC to include information on 
Hospira Hard  Capsules to include information on the 
Labelling and 
the possible risk of hepatotoxicity associated with 
possible risk of hepatotoxicity associated with 
Temozolomidel identified following a cumulative 
review.  The PL has been updated accordingly. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
IB/0005/G 
This was an application for a group of variations. 
08/09/2011 
n/a 
B.I.d.1.z - Stability of AS - Change in the re-test 
period/storage period or storage conditions - Other 
PL 
Temozolomidel identified following a cumulative review.  
The PL has been updated accordingly. Furthermore, 
additional editorial changes have been made to bring the 
SmPC and PL in line with the innovator. Additionally, 
typographical errors in DA, SV, HU, PT and FI annexes were 
corrected. 
Page 17/19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
variation 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.d.1.a.1 - Stability of AS - Change in the re-test 
period/storage period - Reduction 
II/0004 
To increase the shelf-life specification limit in the 
21/07/2011 
21/07/2011 
finished product for Impurity A and for the Total 
Impurities. 
B.II.d.1.f - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
specification parameter which may have a significant 
effect on the overall quality of the finished product 
II/0001/G 
This was an application for a group of variations. 
14/04/2011 
27/05/2011 
SmPC, Annex 
To reduce the amount of desiccant and to replace the 
desiccant disc with a 0.25 g desiccant pouch. 
To restrict the special storage condition to "Do not 
II, Labelling 
and PL 
Page 18/19 
 
 
 
 
 
 
 
 
 
 
 
 
store above 25°C".  
To reduce the shelf-life from 2 years to 1 year for all 
capsules strengths 
To change the medicinal product's release and shelf-
life specification 
To delete all HDPE bottle presentations  
This variation is linked to the quality defect with 
broken capsules and therefore submitted as a Type 
II variation. The MAH has identified the desiccant to 
be the root cause.   
In addition, the MAH has taken the opportunity to 
delete the version number of the DDPS in Annex II. 
B.II.e.1.b.2 - Change in immediate packaging of the 
finished product - Type of container - Sterile 
medicinal products and biological/immunological 
medicinal products 
B.II.e.5.b - Change in pack size of the finished 
product - Deletion of a pack size(s) 
IA/0003 
B.II.d.2.a - Change in test procedure for the finished 
01/12/2010 
n/a 
product - Minor changes to an approved test 
procedure 
IA/0002 
B.II.b.1.a - Replacement or addition of a 
03/11/2010 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
Page 19/19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
